A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials ...
Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...
A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.
ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
Currently, the most widely used vaccine against TB is the Bacillus Calmette-Guérin (BCG). Developed in 1921, the vaccine ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...
Researchers from Australia have developed a groundbreaking mRNA vaccine against tuberculosis (TB), showing promising results in pre-clinical mouse trials. This innovative vaccine could outperform the ...
Australian researchers have developed a new mRNA vaccine for tuberculosis, showing effective results in mice. The vaccine ...
The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...
The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.
ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...
A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials, as part of a successful ...